Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01703364 | Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL | completed | Phase 1 / Phase 2 | 12 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2016 | clinicaltrials |
| NCT01034553 | Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 26 | Mayo ClinicOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT01562990 | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | completed | Phase 1 / Phase 2 | 11 | The Lymphoma Academic Research OrganisationOTHER | 2 | May 23, 2016 | clinicaltrials |
| NCT01376401 | Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00406978 | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients(MPTD) | completed | Phase 1 / Phase 2 | 24 | Silvio AimeOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT00961467 | RMPT for Relapsed/Refractory Multiple Myeloma(RMPT) | completed | Phase 2 | 44 | Fondazione EMN Italy OnlusOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT01501370 | Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy(ZLd_Ld) | withdrawn | Phase 2 | 0 | Tiziana MarangonOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02758925 | CyBeR Association in Relapsed/Refractory DLBCL(CyBeR-Lymph) | unknown | Phase 2 | 78 | University Hospital, CaenOTHER | 0 | May 4, 2016 | clinicaltrials |
| NCT02533401 | A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 2 | May 2, 2016 | clinicaltrials |
| NCT00833833 | MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 259 | Celgene CorporationINDUSTRY | 2 | Apr 27, 2016 | clinicaltrials |
| NCT02753062 | Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma(PTLD) | unknown | Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00831597 | Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(904) | completed | Phase 2 | 61 | PharmatechINDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT01578343 | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma(ZOLINZA) | terminated | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy | terminated | Phase 1 / Phase 2 | 62 | CephalonINDUSTRY | 1 | Apr 11, 2016 | clinicaltrials |
| NCT00250926 | Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2016 | clinicaltrials |
| NCT02140840 | UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Apr 7, 2016 | clinicaltrials |
| NCT00532129 | A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia. | completed | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Apr 6, 2016 | clinicaltrials |
| NCT01394354 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)(VBDD) | completed | Phase 1 / Phase 2 | 34 | University Hospital FreiburgOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen | terminated | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01450215 | Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma | completed | Phase 2 | 62 | Karolinska University HospitalOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT02388581 | First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL | unknown | Phase 2 | 30 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT00999830 | Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma(REMYKIR) | completed | Phase 2 | 27 | Innate PharmaINDUSTRY | 1 | Mar 24, 2016 | clinicaltrials |
| NCT02412267 | Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)(DLBL) | completed | Phase 2 | 17 | National Cancer Centre, SingaporeOTHER | 1 | Mar 23, 2016 | clinicaltrials |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00836173 | Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 2 | 0 | Loyola UniversityOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01457144 | Study of Mantle Cell Lymphoma Treatment by RiBVD(RIBVD) | completed | Phase 2 | 76 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01541332 | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 70 | OncotherapeuticsINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00618969 | Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors | completed | Phase 2 | 2 | University of ArizonaOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT01523860 | Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma(FLE09) | completed | Phase 2 | 76 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 1, 2016 | clinicaltrials |
| NCT00123773 | Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence | completed | Phase 2 | 1,075 | AHS Cancer Control AlbertaOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01352338 | Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)(REPEAT) | completed | Phase 1 / Phase 2 | 82 | UMC UtrechtOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01094548 | Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy | completed | Phase 2 | 34 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00761384 | High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma(HITT) | completed | Phase 1 / Phase 2 | 7 | Lund University HospitalOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT00337259 | Gemcitabine for Marginal Zone Lymphoma | terminated | Phase 2 | 43 | Asan Medical CenterOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)(VEIL) | terminated | Phase 2 | 1 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT01329289 | SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | withdrawn | Phase 2 | 0 | University of PittsburghOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00280241 | Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 2 | 65 | University of PittsburghOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT00438880 | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT01799083 | Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas(CIK) | unknown | Phase 1 / Phase 2 | 100 | Han weidongOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01886976 | Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138(CART-138) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01510756 | Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 4 | Thomas KippsOTHER | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01419691 | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 15 | University of Kansas Medical CenterOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT00381004 | FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT01314014 | Imexon for Relapsed Follicular and Aggressive Lymphomas(ULYM11011) | completed | Phase 2 | 22 | University of RochesterOTHER | 1 | Jan 6, 2016 | clinicaltrials |
| NCT00453102 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma | completed | Phase 2 | 18 | University of MiamiOTHER | 1 | Jan 1, 2016 | clinicaltrials |
Data updated 24 days agoSource updated May 26, 2016source: clinicaltrials